Fradafiban

Drug Profile

Fradafiban

Alternative Names: BIBU 52; BIBU 52 ZW

Latest Information Update: 13 Jun 2001

Price : $50

At a glance

  • Originator Boehringer Ingelheim Pharma KG
  • Class Antiplatelets; Biphenyl compounds; Pyrrolidines; Small molecules
  • Mechanism of Action Fibrinogen receptor antagonists; GPIIb-IIIa antagonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Thrombosis; Unstable angina pectoris

Most Recent Events

  • 13 Jun 2001 Discontinued-II for Unstable angina pectoris in Europe (IV)
  • 13 Jun 2001 Discontinued-II for Thrombosis in Europe (IV)
  • 13 Jun 2001 Discontinued-II for Unstable angina pectoris in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top